MedTrace Logo

Effect of Remimazolam and Sevoflurane Anesthesia on Recovery in Pediatric Patients

NCT06053489 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 146

Last updated 2024-11-01

No results posted yet for this study

Summary

The most commonly used anesthetic for general anesthesia in pediatric patients is sevoflurane, an inhalation anesthetic. However, the incidence of emergence agitation after sevoflurane anesthesia in pediatric patients is high, with reports of up to 67%. Remimazolam (Byfavo Inj., Hana Pharm Col, Ltd., Seoul, Korea) has a short context-sensitive half-life of 7.5 minutes, and the time it takes from the end of anesthesia until the patient wakes up is predictable. According to a study by Yang X et al., administering a small amount of remimazolam (0.2 mg/kg) intravenously at the end of general anesthesia using sevoflurane reduced the incidence of emergence agitation. However, very few studies have evaluated the use of remimazolam in general anesthesia in pediatric patients.

Conditions

  • Ophthalmic Abnormalities
  • Pediatric Disorder

Interventions

OTHER

general anesthesia with remimazolam

general anesthesia with remimazolam in pediatric patients undergoing ophthalmic surgery

Sponsors & Collaborators

  • Pusan National University Yangsan Hospital

    lead OTHER

Principal Investigators

  • Hee Young Kim, MD, PhD · Pusan National University Yangsan Hospital, Yangsan, South Korea

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06053489 on ClinicalTrials.gov